Additionally, both metformin and 2DG have been shown to impact programmed death ligand 1 (PD-L1) glycosylation and degradation in breast cancer cells [42,43,44]; however, the effect of their combination on PD-L1 expression has not yet been studied. Here, CD274 is linked to breast cancer.